A Study of TAK-360 in Adults With Idiopathic Hypersomnia

Description

Idiopathic Hypersomnia (IH) is a condition where people feel extremely sleepy during the day, especially in the morning, even if they sleep a lot at night. They may have trouble waking up in the morning, no matter how much they sleep (sometimes more than 11 hours per day), and they can't help feeling tired, even after taking daytime naps. Because of this sleepiness, they may have trouble focusing, thinking clearly, or keeping up with daily activities. They may also have symptoms like dizziness or feeling lightheaded. Orexin is a chemical made in the brain that helps keep a person awake and alert. TAK-360 acts like orexin. Previous studies have shown that medicines that act like orexin may keep people awake. The main aim of this study is to learn how safe TAK-360 is and how well adults with IH tolerate it. Researchers also want to find out if TAK-360 can help people with IH stay awake and how much TAK-360 is needed to do that. Participants will be randomly (by chance, like drawing names from a hat) chosen to receive either TAK-360 or a placebo. The placebo looks just like TAK-360 but does not have any medicine in it. Using a placebo helps researchers learn about the real effect of the treatment.

Conditions

Idiopathic Hypersomnia

Talk to us

Study Overview

On this page

Study Details

Study overview

Idiopathic Hypersomnia (IH) is a condition where people feel extremely sleepy during the day, especially in the morning, even if they sleep a lot at night. They may have trouble waking up in the morning, no matter how much they sleep (sometimes more than 11 hours per day), and they can't help feeling tired, even after taking daytime naps. Because of this sleepiness, they may have trouble focusing, thinking clearly, or keeping up with daily activities. They may also have symptoms like dizziness or feeling lightheaded. Orexin is a chemical made in the brain that helps keep a person awake and alert. TAK-360 acts like orexin. Previous studies have shown that medicines that act like orexin may keep people awake. The main aim of this study is to learn how safe TAK-360 is and how well adults with IH tolerate it. Researchers also want to find out if TAK-360 can help people with IH stay awake and how much TAK-360 is needed to do that. Participants will be randomly (by chance, like drawing names from a hat) chosen to receive either TAK-360 or a placebo. The placebo looks just like TAK-360 but does not have any medicine in it. Using a placebo helps researchers learn about the real effect of the treatment.

A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants With Idiopathic Hypersomnia (IH)

A Study of TAK-360 in Adults With Idiopathic Hypersomnia

Condition
Idiopathic Hypersomnia
Intervention / Treatment

-

Contacts and Locations

Redwood City

Takeda Site 11, Redwood City, California, United States, 94063

Santa Ana

Takeda Site 10, Santa Ana, California, United States, 92705

Brandon

Takeda Site 19, Brandon, Florida, United States, 33511

Winter Park

Takeda Site 14, Winter Park, Florida, United States, 32789

Denver

Takeda Site 16, Denver, North Carolina, United States, 28037

Huntersville

Takeda Site 15, Huntersville, North Carolina, United States, 28078-5082

Cincinnati

Takeda Site 12, Cincinnati, Ohio, United States, 45245

Cincinnati

Takeda Site 17, Cincinnati, Ohio, United States, 45245

Columbia

Takeda Site 13, Columbia, South Carolina, United States, 29201

San Antonio

Takeda Site 18, San Antonio, Texas, United States, 78229

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. The participant weighs greater than or equal to (≥) 40 kilograms (kg) and has a body mass index (BMI) between 16 and 38 kilograms per meter square (kg/m\^2) \[inclusive\].
  • 2. The participant has a documented, current diagnosis of IH.
  • 1. The participant has a current medical disorder associated with excessive daytime sleepiness (EDS) \[other than IH\].
  • 2. The participant has medically significant thyroid disease.
  • 3. The participant has a history of cancer in the past 5 years. (This exclusion does not apply to participants with carcinoma in situ \[such as basal cell carcinoma\] that has been treated and is stable, or who have been stable without further treatment. These participants may be included after approval by the medical monitor.)
  • 4. The participant has any of the following viral infections based on a positive test result: Hepatitis B surface antigen (at screening), hepatitis C virus antibody (at screening), human immunodeficiency virus (HIV) antibody/antigen (at screening).
  • 5. The participant has a clinically significant history of head injury or head trauma.
  • 6. The participant has history of epilepsy, seizure, or convulsion (exception for a single febrile seizure in childhood).
  • 7. The participant has a history of cerebral ischemia, transient ischemic attack (less than \[\<\]5 years from screening), intracranial aneurysm, or arteriovenous malformation.

Ages Eligible for Study

18 Years to 70 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Takeda,

Study Director, STUDY_DIRECTOR, Takeda

Study Record Dates

2026-02-19